Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Aurinia Pharmaceuticals Inc.'s quarterly P/E stands at 2.6x, down 98.8% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 71.4% YoY to 29.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.85 | 2.61 | 12.01 | 14.12 | 12.56 | 224.50 | 18.60 | 142.75 | — | — | — | — | — |
| — | -98.8% | -35.4% | -90.1% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.59 | 7.17 | 5.11 | 4.33 | 4.47 | 5.54 | 3.94 | 3.60 | 3.59 | 7.16 | 5.09 | 8.33 | 11.36 |
| — | +29.5% | +29.9% | +20.4% | +24.7% | -22.6% | -22.6% | -56.8% | -68.4% | +32.5% | +6.5% | -34.1% | -44.0% | |
| P/B Ratio | 3.88 | 3.81 | 4.11 | 3.62 | 3.19 | 3.51 | 2.75 | 2.26 | 2.01 | 3.42 | 2.83 | 3.52 | 4.00 |
| — | +8.3% | +49.3% | +60.3% | +58.9% | +2.8% | -2.9% | -35.9% | -49.9% | +125.4% | +12.4% | +4.8% | +2.3% | |
| P/FCF | 15.88 | 12.13 | 8.47 | 6.87 | 217.63 | 11.03 | 15.75 | 13.09 | — | 22.65 | — | — | — |
| — | +10.0% | -46.3% | -47.5% | — | -51.3% | — | — | — | +52.1% | — | — | — | |
| EV / EBITDA | 20.44 | 29.58 | 10.89 | 12.44 | 10.56 | 103.51 | 16.80 | 65.72 | — | — | — | — | — |
| — | -71.4% | -35.2% | -81.1% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 20.44 | — | 11.79 | 13.34 | 11.10 | 142.52 | 17.46 | 81.79 | — | — | — | — | — |
| — | — | -32.4% | -83.7% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Aurinia Pharmaceuticals Inc.'s operating margin was 43.1% in Q4 2025, up 2.6 pp QoQ and up 45.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 36.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 89.0% | 88.4% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% | 96.2% | 98.8% |
| — | -1.9% | -2.9% | +6.4% | +2.0% | +3.1% | +4.0% | -12.3% | -14.4% | -7.5% | -8.4% | +2.0% | -0.0% | |
| Operating Margin | 37.1% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% | -2.6% | -21.3% | -65.8% | -29.8% | -39.0% | -86.0% |
| — | +1646.2% | +133.6% | +1184.4% | +264.5% | +95.8% | +158.1% | +93.2% | +75.3% | +33.4% | -75.2% | +69.5% | +50.9% | |
| Net Margin | 101.5% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | -21.4% | -59.6% | -24.7% | -27.7% | -76.2% |
| — | +11351.8% | +102.8% | +2334.2% | +274.9% | +104.0% | +185.8% | +104.6% | +71.9% | +34.9% | -53.1% | +78.0% | +56.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 44.5% | 9.0% | 6.3% | 6.4% | 0.4% | 3.8% | 0.2% | -2.9% | -7.0% | -3.4% | -2.9% | -6.6% |
| — | +11821.1% | +136.0% | +3047.8% | +320.1% | +105.3% | +211.2% | +106.8% | +55.7% | -11.1% | -61.6% | +64.0% | +18.9% | |
| ROA | 44.1% | 33.0% | 6.1% | 4.3% | 4.4% | 0.3% | 2.7% | 0.1% | -2.0% | -4.9% | -2.4% | -2.3% | -5.7% |
| — | +12586.5% | +129.0% | +2977.0% | +319.1% | +105.3% | +209.8% | +106.0% | +64.5% | +10.3% | -31.5% | +68.0% | +20.7% | |
| ROIC | 16.6% | 5.3% | 6.1% | 4.2% | 4.5% | -0.3% | 2.1% | -0.3% | -2.0% | -5.1% | -2.9% | -3.4% | -7.1% |
| — | +1808.2% | +194.9% | +1564.5% | +325.2% | +94.0% | +171.8% | +91.6% | +71.9% | +18.9% | -26.0% | +62.3% | +27.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Aurinia Pharmaceuticals Inc.'s Debt/EBITDA ratio is 4.0x, up from 2.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 14.9% YoY to 5.25x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.21 | 0.24 | 0.22 | 0.21 | 0.23 | 0.24 | 0.25 | 0.26 | 0.24 | 0.26 | 0.02 |
| — | -38.8% | -5.6% | +3.5% | -9.7% | -18.6% | -4.8% | -8.6% | +1112.4% | +1194.6% | +1130.0% | +1204.0% | +6.2% | |
| Debt / EBITDA | 0.71 | 4.01 | 2.26 | 3.28 | 2.92 | 24.86 | 5.28 | 25.82 | — | — | — | — | — |
| — | -83.9% | -57.2% | -87.3% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.25 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 | 5.77 | 6.75 | 10.08 |
| — | +14.9% | +2.7% | -1.9% | +5.8% | -17.0% | -2.9% | -21.0% | -44.4% | -42.7% | -47.6% | -48.5% | -28.6% | |
| Quick Ratio | 4.76 | 4.76 | 5.17 | 4.63 | 5.26 | 4.17 | 5.11 | 4.82 | 5.05 | 4.99 | 5.33 | 6.21 | 9.32 |
| — | +14.3% | +1.1% | -4.0% | +4.2% | -16.5% | -4.1% | -22.3% | -45.9% | -44.9% | -48.8% | -49.7% | -30.1% | |
| Interest Coverage | — | — | — | 17.98 | 20.48 | -1.46 | 9.73 | -1.26 | -8.34 | -22.65 | -11.62 | -248.77 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying AUPH stock.
Aurinia Pharmaceuticals Inc.'s current P/E is 7.8x. The average P/E over the last 4 quarters is 10.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aurinia Pharmaceuticals Inc.'s current operating margin is 37.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aurinia Pharmaceuticals Inc.'s business trajectory between earnings reports.